BG64168B1 - Бързоразтворима таблета на галантамин хидробромид - Google Patents

Бързоразтворима таблета на галантамин хидробромид Download PDF

Info

Publication number: BG64168B1
Authority: BG; Bulgaria
Prior art keywords: tablet; sample; tablet according; film coating; disintegrant
Prior art date: 1996-06-14

Application number

BG102991A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102991A (en

Inventor

Paul M. Gilis

Valentin F. De Conde

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-14

Filing date

1998-12-04

Publication date

2004-03-31

1998-12-04 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

1999-08-31 Publication of BG102991A publication Critical patent/BG102991A/xx

2004-03-31 Publication of BG64168B1 publication Critical patent/BG64168B1/bg

Links

ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims description 54
229960003980 galantamine Drugs 0.000 title claims description 35
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title description 19
239000000203 mixture Substances 0.000 claims abstract description 25
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 13
229960001021 lactose monohydrate Drugs 0.000 claims abstract description 13
239000003795 chemical substances by application Substances 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
239000007888 film coating Substances 0.000 claims description 23
238000009501 film coating Methods 0.000 claims description 23
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
239000008108 microcrystalline cellulose Substances 0.000 claims description 16
229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
238000002156 mixing Methods 0.000 claims description 13
235000019359 magnesium stearate Nutrition 0.000 claims description 12
239000007884 disintegrant Substances 0.000 claims description 11
239000011363 dried mixture Substances 0.000 claims description 9
239000000314 lubricant Substances 0.000 claims description 9
239000000377 silicon dioxide Substances 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
238000000576 coating method Methods 0.000 claims description 8
239000011248 coating agent Substances 0.000 claims description 7
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
229920000642 polymer Polymers 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
229960005168 croscarmellose Drugs 0.000 claims description 2
229920006037 cross link polymer Polymers 0.000 claims description 2
238000004132 cross linking Methods 0.000 claims description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
238000000151 deposition Methods 0.000 claims description 2
239000004014 plasticizer Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
238000004090 dissolution Methods 0.000 abstract description 12
QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 abstract description 12
229960002024 galantamine hydrobromide Drugs 0.000 abstract description 9
238000002360 preparation method Methods 0.000 abstract description 9
238000000034 method Methods 0.000 abstract description 4
239000001913 cellulose Substances 0.000 abstract description 3
238000003825 pressing Methods 0.000 abstract description 2
238000000889 atomisation Methods 0.000 abstract 1
229920002678 cellulose Polymers 0.000 abstract 1
238000000354 decomposition reaction Methods 0.000 abstract 1
239000003826 tablet Substances 0.000 description 51
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 12
239000000454 talc Substances 0.000 description 10
229910052623 talc Inorganic materials 0.000 description 10
239000004408 titanium dioxide Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 7
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 7
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 7
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 7
239000008213 purified water Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000007907 direct compression Methods 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
239000008101 lactose Substances 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
229920003125 hypromellose 2910 Polymers 0.000 description 4
229940031672 hypromellose 2910 Drugs 0.000 description 4
229960003511 macrogol Drugs 0.000 description 4
239000007944 soluble tablet Substances 0.000 description 4
DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
239000003814 drug Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
229940100445 wheat starch Drugs 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 2
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000003797 alkaloid derivatives Chemical group 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000013383 initial experiment Methods 0.000 description 2
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
230000037317 transdermal delivery Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
DKXNBNKWCZZMJT-JVCRWLNRSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DKXNBNKWCZZMJT-JVCRWLNRSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
JPVBTFOTYRZBLR-UHFFFAOYSA-N 2h-2-benzazepin-6-ol Chemical compound N1C=CC=C2C(O)=CC=CC2=C1 JPVBTFOTYRZBLR-UHFFFAOYSA-N 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000001375 Facial Neuralgia Diseases 0.000 description 1
241000234271 Galanthus Species 0.000 description 1
241001502107 Galanthus alpinus Species 0.000 description 1
241000234283 Galanthus nivalis Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
208000012790 cranial neuralgia Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
-1 macrogol 6000 Chemical compound 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000047 product Substances 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BG102991A 1996-06-14 1998-12-04 Бързоразтворима таблета на галантамин хидробромид BG64168B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96201676		1996-06-14
PCT/EP1997/002986 WO1997047304A1 (en)	1996-06-14	1997-06-06	Fast-dissolving galanthamine hydrobromide tablet

Publications (2)

Publication Number	Publication Date
BG102991A BG102991A (en)	1999-08-31
BG64168B1 true BG64168B1 (bg)	2004-03-31

Family

ID=8224084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102991A BG64168B1 (bg)	1996-06-14	1998-12-04	Бързоразтворима таблета на галантамин хидробромид

Country Status (32)

Country	Link
US (2)	US6099863A (de)
EP (1)	EP0915701B1 (de)
JP (1)	JP4172820B2 (de)
KR (1)	KR100358676B1 (de)
CN (1)	CN1102390C (de)
AR (2)	AR008237A1 (de)
AT (1)	ATE285777T1 (de)
AU (1)	AU726212B2 (de)
BG (1)	BG64168B1 (de)
BR (1)	BR9709729A (de)
CA (1)	CA2257431C (de)
CZ (1)	CZ295226B6 (de)
DE (1)	DE69732113T2 (de)
DK (1)	DK0915701T3 (de)
EA (1)	EA001193B1 (de)
EE (1)	EE03337B1 (de)
ES (1)	ES2235234T3 (de)
HR (1)	HRP970321B1 (de)
ID (1)	ID17088A (de)
IL (1)	IL127519A (de)
MY (1)	MY121669A (de)
NO (1)	NO322892B1 (de)
NZ (1)	NZ333280A (de)
PL (1)	PL189329B1 (de)
PT (1)	PT915701E (de)
SI (1)	SI0915701T1 (de)
SK (1)	SK284620B6 (de)
TR (1)	TR199802592T2 (de)
TW (1)	TW506836B (de)
UA (1)	UA62930C2 (de)
WO (1)	WO1997047304A1 (de)
ZA (1)	ZA975281B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440457B1 (en) *	1993-05-27	2002-08-27	Alza Corporation	Method of administering antidepressant dosage form
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
KR100437105B1 (ko) *	1998-12-24	2004-06-23	얀센 파마슈티카 엔.브이.	방출 조절형 갈란타민 조성물
US20050063998A1 (en) *	1999-10-26	2005-03-24	Francois Marc Karel Jozef	Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) *	2000-02-11	2003-09-30	Eurand Pharmaceuticals Ltd.	Timed pulsatile drug delivery systems
AU5702201A (en) *	2000-04-13	2001-10-30	Mayo Foundation	Abeta<sub>42</sub> lowering agents
SE521512C2 (sv) *	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US6500454B1 (en) *	2001-10-04	2002-12-31	Eurand Pharmaceuticals Ltd.	Timed, sustained release systems for propranolol
CN100528164C (zh) *	2002-04-02	2009-08-19	詹森药业有限公司	用于增强认知保养的抑制素产品
DE10235556A1 (de) *	2002-08-03	2004-02-19	Hf Arzneimittelforschung Gmbh	Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040097484A1 (en) *	2002-11-14	2004-05-20	Marc Cantillion	Once a day galantamine pharmaceutical compositions and methods of use
DK1803443T3 (en) *	2002-12-20	2019-02-25	Niconovum Ab	Nicotine-containing particulate material with a crystalline cellulose
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
WO2004071431A2 (en) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Method and composition for treating neurodegenerative disorders
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (de) *	2003-08-19	2017-08-31	Janssen Pharmaceutica N.V.	Buccale Formulierungen des Galanthamins und deren Anwendungen
MXPA06002257A (es) *	2003-08-26	2006-05-17	Shire Holdings Ag	Farmaceutica que comprende compuestos de lantano.
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
WO2005051489A2 (en) *	2003-11-28	2005-06-09	Ranbaxy Laboratories Limited	Fast dissolving solid oral dosage forms of galanthamine
WO2005065662A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Solid dosage formulations of galantamine
EP2340813A1 (de) *	2003-12-31	2011-07-06	Actavis Group PTC ehf.	Feste Darreichungsformen von Galantamin
WO2005065661A2 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Immediate, controlled and sustained release formulations of galanthamine
WO2006020850A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) *	2004-08-11	2008-06-10	Myriad Genetics Inc	composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
CN101044200A (zh) *	2004-09-24	2007-09-26	巴尔的摩马里兰大学	治疗有机磷中毒的方法
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
AU2005299490C1 (en)	2004-10-21	2012-01-19	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
AU2005308575A1 (en) *	2004-11-23	2006-06-01	Warner-Lambert Company Llc	7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20080145422A1 (en) *	2005-02-10	2008-06-19	Roxane Laboratories, Inc.	Galantamine tablet formulation
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
GB0516604D0 (en) *	2005-08-12	2005-09-21	Sandoz Ag	Rapidly dispersing/disintegrating compositions
US8168219B2 (en) *	2005-11-30	2012-05-01	Isp Investments Inc.	Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
CA2646942C (en)	2006-03-16	2014-07-29	Modoral Brands Inc.	Improved snuff composition
HUE029173T2 (hu) *	2006-04-26	2017-02-28	Alphapharm Pty Ltd	Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
GB0612540D0 (en) *	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
WO2008008120A1 (en) *	2006-07-14	2008-01-17	Fmc Corporation	Solid form
CN100438917C (zh) *	2006-07-20	2008-12-03	山东聊城阿华制药有限公司	一种微晶纤维素乳糖的制备方法
WO2008062426A2 (en) *	2006-08-02	2008-05-29	Emcure Pharmaceuticals Limited	Formulation of benzazepine derivatives
BRPI0718437A2 (pt)	2006-10-27	2013-11-19	Medivation Neurology Inc	Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
US20080311162A1 (en) *	2007-05-16	2008-12-18	Olivia Darmuzey	Solid form
PE20091156A1 (es) *	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2116232B1 (de)	2008-05-09	2012-02-15	Ratiopharm GmbH	Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
KR101765357B1 (ko)	2009-12-02	2017-08-04	아데어 파마수티컬스 에스.알.엘.	펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (ja) *	2011-03-09	2015-01-21	塩野義製薬株式会社	ガランタミンを含有する口腔内崩壊錠剤
ES2888074T3 (es)	2013-08-16	2021-12-30	Univ Maastricht	Tratamiento del deterioro cognitivo con inhibidor de PDE4
CN106822008A (zh) *	2017-01-11	2017-06-13	江苏艾兰得营养品有限公司	一种维生素d速溶制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3506276C1 (de) *	1985-02-22	1986-04-24	Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring	Direkttablettiermittel
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
EP0584185B1 (de) *	1991-05-14	1999-08-11	Ernir Snorrason	Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) *	1991-05-14	1994-08-09	Ernir Snorrason	Method of treating mania in humans
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet

1997
- 1997-05-19 TW TW086106622A patent/TW506836B/zh not_active IP Right Cessation
- 1997-06-06 WO PCT/EP1997/002986 patent/WO1997047304A1/en not_active Ceased
- 1997-06-06 EE EE9800429A patent/EE03337B1/xx unknown
- 1997-06-06 TR TR1998/02592T patent/TR199802592T2/xx unknown
- 1997-06-06 KR KR10-1998-0709401A patent/KR100358676B1/ko not_active Expired - Lifetime
- 1997-06-06 US US09/202,187 patent/US6099863A/en not_active Expired - Lifetime
- 1997-06-06 PL PL97330431A patent/PL189329B1/pl unknown
- 1997-06-06 BR BR9709729A patent/BR9709729A/pt not_active IP Right Cessation
- 1997-06-06 DK DK97927159T patent/DK0915701T3/da active
- 1997-06-06 NZ NZ333280A patent/NZ333280A/en not_active IP Right Cessation
- 1997-06-06 EA EA199900026A patent/EA001193B1/ru not_active IP Right Cessation
- 1997-06-06 JP JP50118198A patent/JP4172820B2/ja not_active Expired - Lifetime
- 1997-06-06 IL IL12751997A patent/IL127519A/en not_active IP Right Cessation
- 1997-06-06 EP EP97927159A patent/EP0915701B1/de not_active Expired - Lifetime
- 1997-06-06 SK SK1696-98A patent/SK284620B6/sk not_active IP Right Cessation
- 1997-06-06 AU AU31743/97A patent/AU726212B2/en not_active Expired
- 1997-06-06 CZ CZ19984034A patent/CZ295226B6/cs not_active IP Right Cessation
- 1997-06-06 CA CA002257431A patent/CA2257431C/en not_active Expired - Lifetime
- 1997-06-06 SI SI9730690T patent/SI0915701T1/xx unknown
- 1997-06-06 DE DE69732113T patent/DE69732113T2/de not_active Expired - Lifetime
- 1997-06-06 ES ES97927159T patent/ES2235234T3/es not_active Expired - Lifetime
- 1997-06-06 PT PT97927159T patent/PT915701E/pt unknown
- 1997-06-06 AT AT97927159T patent/ATE285777T1/de active
- 1997-06-06 CN CN97195512A patent/CN1102390C/zh not_active Expired - Lifetime
- 1997-06-06 UA UA98126372A patent/UA62930C2/uk unknown
- 1997-06-11 HR HR970321A patent/HRP970321B1/xx not_active IP Right Cessation
- 1997-06-12 MY MYPI97002621A patent/MY121669A/en unknown
- 1997-06-13 ID IDP972025A patent/ID17088A/id unknown
- 1997-06-13 AR ARP970102615A patent/AR008237A1/es active IP Right Grant
- 1997-06-13 ZA ZA975281A patent/ZA975281B/xx unknown
1998
- 1998-12-04 BG BG102991A patent/BG64168B1/bg unknown
- 1998-12-11 NO NO19985815A patent/NO322892B1/no not_active IP Right Cessation
2000
- 2000-06-01 US US09/585,122 patent/US6358527B1/en not_active Expired - Lifetime
2008
- 2008-11-25 AR ARP080105111A patent/AR070670A2/es unknown

Also Published As

Publication number	Publication date
HK1019703A1 (en)	2000-02-25
TR199802592T2 (xx)	1999-03-22
ID17088A (id)	1997-12-04
CN1102390C (zh)	2003-03-05
ES2235234T3 (es)	2005-07-01
IL127519A (en)	2002-07-25
SI0915701T1 (en)	2005-06-30
NO322892B1 (no)	2006-12-18
CZ403498A3 (cs)	1999-03-17
CZ295226B6 (cs)	2005-06-15
PT915701E (pt)	2005-05-31
DE69732113T2 (de)	2005-12-08
MY121669A (en)	2006-02-28
JP4172820B2 (ja)	2008-10-29
ATE285777T1 (de)	2005-01-15
NO985815L (no)	1998-12-11
SK169698A3 (en)	1999-10-08
EP0915701B1 (de)	2004-12-29
EA199900026A1 (ru)	1999-06-24
PL189329B1 (pl)	2005-07-29
SK284620B6 (sk)	2005-07-01
TW506836B (en)	2002-10-21
KR20000015851A (ko)	2000-03-15
HRP970321A2 (en)	1998-04-30
DK0915701T3 (da)	2005-04-25
US6358527B1 (en)	2002-03-19
JP2000511918A (ja)	2000-09-12
DE69732113D1 (de)	2005-02-03
HRP970321B1 (en)	2001-12-31
EP0915701A1 (de)	1999-05-19
IL127519A0 (en)	1999-10-28
EE03337B1 (et)	2001-02-15
CA2257431A1 (en)	1997-12-18
EA001193B1 (ru)	2000-12-25
CA2257431C (en)	2001-11-20
ZA975281B (en)	1998-12-14
BG102991A (en)	1999-08-31
NO985815D0 (no)	1998-12-11
NZ333280A (en)	1999-09-29
AU726212B2 (en)	2000-11-02
AU3174397A (en)	1998-01-07
WO1997047304A1 (en)	1997-12-18
KR100358676B1 (ko)	2003-02-17
AR070670A2 (es)	2010-04-28
UA62930C2 (uk)	2004-01-15
BR9709729A (pt)	1999-08-10
US6099863A (en)	2000-08-08
PL330431A1 (en)	1999-05-10
CN1222077A (zh)	1999-07-07
AR008237A1 (es)	1999-12-29

Publication	Publication Date	Title
CA2257431C (en)	2001-11-20	Fast-dissolving galanthamine hydrobromide tablet
FI89005B (fi)	1993-04-30	Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning
RU2403043C2 (ru)	2010-11-10	Подъязычная таблетка, покрытая оболочкой
US4309406A (en)	1982-01-05	Sustained release pharmaceutical compositions
ZA200403849B (en)	2005-10-26	Pharmaceutical composition
NZ220769A (en)	1990-12-21	Compositions of ketotifen (4-(1-methyl-4-piperidylidene)- 4h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-9(h)-one)
JP2011507973A (ja)	2011-03-10	アムロジピンとバルサルタンとの医薬組成物
US20090264408A1 (en)	2009-10-22	Extended release dosage forms of quetiapine
AU2005263958B2 (en)	2011-04-14	Anti-histaminic composition
CA2247405C (en)	2004-04-20	Slow-release pharmaceutical formulations containing mizolastin
RU2256454C2 (ru)	2005-07-20	Способы получения фармацевтических композиций алкалоидов спорыньи с пролонгированным действием, характеризующихся улучшенной биодоступностью, и содержащие указанные алкалоиды композиции
JP2001511450A (ja)	2001-08-14	チアガビンを含有する制御放出性の医薬組成物
KR102545579B1 (ko)	2023-06-20	iLet (innovation low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용편의성이 증가된 카르베딜롤 서방성 정제
CA2180703A1 (en)	1998-01-09	Fast-dissolving galanthamine hydrobromide tablet
US20050142193A1 (en)	2005-06-30	Galantamine formulations
US20030180354A1 (en)	2003-09-25	Amlodipine maleate formulations
HU226132B1 (en)	2008-05-28	Fast-dissolving galanthamine hydrobromide tablet
HK1019703B (en)	2005-04-01	Fast-dissolving galanthamine hydrobromide tablet
AU2012202717B2 (en)	2014-06-26	Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
HK1068539A1 (en)	2005-04-29	Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HK1068539B (en)	2006-04-21	Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient